arrow
J

Jesús Troya

hospital universitario infanta leonor
H指数:34
被引数:9,945

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Incident and Recurrent Sexually Transmitted Infections by Gender Identity Among Sex Workers on HIV Pre-Exposure Prophylaxis: A Prospective Cohort Study

性工作者中接受HIV暴露前预防者的初次和复发性性传播感染按性别身份的分布:一项前瞻性队列研究

2026-10-070
OAAI
Effectiveness and Persistence of Long-Acting Injectable Cabotegravir and Rilpivirine in Migrant Individuals Living With HIV in Spain: Substudy of the RELATIVITY Cohort

长效注射用卡博特gravir和 rilpivirine在西班牙HIV感染者中的有效性与持久性:RELATIVITY队列研究的子研究

2026-04-210
OAAI
Long-acting cabotegravir and rilpivirine in people with HIV and obesity: Real-world outcomes from the RELATIVITY cohort
2026-01-250
PRE
Clinical outcomes of long-acting cabotegravir and rilpivirine in people with HIV aged 60 and older: Real-world data from the Spanish RELATIVITY cohort

60岁及以上HIV感染者中长期卡博格韦和 rilpivirine 的临床结局:来自西班牙RELATIVITY队列的真实世界数据

2025-10-210
PRE
Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study)

与继续使用多替拉韦/拉米夫定相比,转换为比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺后的炎症和代谢结局相当(INSTINCT/GESIDA10918研究)

2025-10-100
OA
A prospective assessment of the efficacy and durability of long-acting cabotegravir and rilpivirine in individuals with HIV in Spain (RELATIVITY study)

一项关于西班牙HIV感染者中长期卡博格韦(cabotegravir)和利匹韦林(rilpivirine)疗效及持久性的前瞻性评估(RELATIVITY研究)

2025-10-010
PRE
Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children

儿童中与抗ifn-α 相关的新型冠状病毒肺炎肺炎风险高于抗ifn-ω 自身抗体

2024-01-0416
OAAI
Vaccine breakthrough hypoxemic COVID-19 pneumonia in patients with auto-Abs neutralizing type I IFNs

Auto-abs中和I型干扰素患者的疫苗突破性低氧新型冠状病毒肺炎肺炎

2023-12-2243
OAAI
Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens
2023-09-193
PRE